GeNeuro is a clinical-stage biopharmaceutical company focused on understanding and interrupting the causative factors at work in the progression of neurodegenerative and autoimmune diseases.

GeNeuro’s most advanced therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W (W-ENV) family identified as a potential causative factor in multiple sclerosis (MS) and post-COVID syndromes (neurological and psychiatric symptoms affecting COVID-19 patients many months after initial infection with SARS-CoV-2).

GeNeuro has completed Phase II clinical trials in MS and is currently completing a Phase II clinical trial in post-COVID, with results planned for June 2024; subject to financing, the Company is also considering to finalize the preclinical program of its other drug candidate, GNK301, in amyotrophic lateral sclerosis (ALS).

As previously indicated, the Company has frozen its program in Type-1 diabetes to focus its efforts on MS, ALS and post-COVID.